Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Recent & Breaking News (NDAQ:IMNN)

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 11, 2023

IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023

GlobeNewswire May 4, 2023

IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001

GlobeNewswire April 19, 2023

IMUNON Reports 2022 Financial Results and Provides Business Update

GlobeNewswire March 30, 2023

IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023

GlobeNewswire March 23, 2023

IMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023

GlobeNewswire March 22, 2023

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

GlobeNewswire March 21, 2023

IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting

GlobeNewswire March 15, 2023

IMUNON CEO Issues Letter to Shareholders

GlobeNewswire March 1, 2023

IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer

GlobeNewswire February 27, 2023

IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses

GlobeNewswire January 12, 2023

IMUNON Enters into Collaborative Research Agreement with The Wistar Institute's Vaccine & Immunotherapy Center to Research IMUNON's PLACCINE Vaccine Platform

GlobeNewswire January 5, 2023

IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

GlobeNewswire December 14, 2022

IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages

GlobeNewswire December 1, 2022

IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 - December 1, 2022

GlobeNewswire November 22, 2022

IMUNON Announces Strategic Investment in Transomic Technologies

GlobeNewswire November 17, 2022

IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 14, 2022

IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON's PLACCINE Plasmid DNA with Acuitas' Lipid Nanoparticle Delivery System

GlobeNewswire November 10, 2022

Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022

GlobeNewswire November 7, 2022

Imunon Appoints James E. Dentzer to its Board of Directors

GlobeNewswire October 3, 2022